SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 755.11 |
| Enterprise Value ($M) | 705.30 |
| Book Value ($M) | 168.75 |
| Book Value / Share | 2.84 |
| Price / Book | 4.47 |
| NCAV ($M) | 107.04 |
| NCAV / Share | 1.80 |
| Price / NCAV | 7.05 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.73 |
| Return on Assets (ROA) | -0.39 |
| Return on Equity (ROE) | -0.53 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.86 |
| Current Ratio | 2.86 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 250.97 |
| Assets | 312.67 |
| Liabilities | 143.93 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 76.99 |
| Operating Income | -155.06 |
| Net Income | -143.95 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -81.36 |
| Cash from Investing | 68.30 |
| Cash from Financing | 3.22 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Price T Rowe Associates Inc /md/ | 4.90 | -26.49 | |
| 13G/A | Baker Bros. Advisors Lp | 9.99 | 3.13 | |
| 13G/A | Redmile Group, LLC | 9.90 | 2.49 | |
| 13G | Sands Arthur T | 5.40 | ||
| 13G/A | Deep Track Capital, LP | 6.18 | 10.33 | |
| 13G | Vanguard Group Inc | 5.36 | ||
| 13G | Morgan Stanley | 6.40 | ||
| 13G/A | Wasatch Advisors Inc | |||
| 13G | ARK Investment Management LLC | 6.59 | ||
| 13G/A | BlackRock Inc. | 9.60 | 12.10 | |
| 13G/A | State Street Corp | 1.90 | -63.26 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 62,004 | 386,462 | 16.04 | |
| 47,919 | 374,987 | 12.78 | |
| 70,626 | 439,010 | 16.09 | |
| 71,857 | 346,503 | 20.74 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| NAMS – NewAmsterdam Pharma Company N.V. | NGNE – Neurogene Inc. |
| NKGN – NKGen Biotech, Inc. | NTLA – Intellia Therapeutics, Inc. |
| OCS – Oculis Holding AG |
Financial data and stock pages provided by
Fintel.io